Technology ID

Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN

Lead Inventor
Leroith, Derek
Quon, Michael
Research Materials
Therapeutic Areas
Development Status
The technology is currently in the pre-clinical stage of development.
Lead IC
PTEN is a tumor suppressor gene that is frequently deleted or mutated in a variety of human cancers, including prostate, breast, endometrial, lung, and ovarian cancers. In prostate cancer cells, PTEN deletion is the most common event observed. The loss of PTEN is thought to play and important role in tumor cell proliferation and metastasis due to a lack of control of the signaling pathways that mediate cellular processes such as apoptosis and migration. Previously PTEN had been shown to down regulate cyclin D1 expression as well as regulate p53 protein levels and transcriptional activity, and recently the inventors of this technology have shown that PTEN decreases surface IGF-IR protein levels in prostate cancer cell lines in an Akt-independent manner.

PC3 cells are prostate cancer cells that lack PTEN gene. This technology describes PC3 cells that overexpress the PTEN gene. These cell lines can be used to study the role of the PTEN gene in cancer growth and metastasis.
Licensing Contact:
Specialist (ALS), Admin. Licensing